Pruritus in Patients Under Targeted Anticancer Therapy: A
Pruritus related to trastuzumab and pertuzumab in HER2 + breast
Antibody-Based Biotherapeutics in Cancer
A randomized, controlled phase II trial of neoadjuvant ado
Pertuzumab in human epidermal growth-factor receptor 2-positive
Pertuzumab (Perjeta) Drug Information
ESMO: Final Overall Survival Analysis: HER2-Positive Metastatic
Targeted treatments of HER2-positive metastatic breast cancer
Pertuzumab, trastuzumab, and docetaxel for HER2-positive
Skin Lesions in Patient With Metastatic Breast Cancer
PDF] Mechanisms Underlying the Action and Synergism of Trastuzumab
Real World Evidence of Neoadjuvant Docetaxel/Carboplatin
Phase I study of LZM005 in patients with HER2-positive metastatic